Eli Lilly CEO: $25B deal spree targets post-obesity growth into 2030s
Eli Lilly CEO says the company’s $25B deal spree is about building growth beyond obesity into the 2030s.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.